Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6574377 | 0.82 | CA12 (0.47) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL6572878 | 0.72 | POLB (0.40) | CA12CA1CA2CA9 | |
| SCHEMBL8325135 | 0.69 | CA12 (0.40) | CA12CA1CA2CA9 | |
| SCHEMBL28807614 | 0.69 | CA12 (0.49) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL4608993 | 0.69 | CA12 (0.43) | CA12CA1CA2CA9 | |
| SCHEMBL11436786 | 0.67 | KDM4E (0.40) | NPC1 | |
| SCHEMBL15442132 | 0.67 | CA12 (0.44) | CA12CA1CA2CA9 | |
| SCHEMBL4610878 | 0.67 | CA12 (0.47) | CA12CA1CA2CA9 | |
| SCHEMBL12914051 | 0.66 | CA12 (0.40) | CA12CA1CA2CA9 | |
| Hydrochloric Acid SCHEMBL2542251 | 0.66 | CA12 (0.46) | CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248897-A1 | Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-12-09 | — | — | US | disclosed |
| EP-1414790-A1 | SUBSTITUTED N-ACYL ANILINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003000653-A1 | SUBSTITUTED N-ACYL ANILINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG (DE) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248897-A1 | Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions | NAT1, CYP3A5, CYP3A7 | CA12 1235/4885CA1 621/4885CA2 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.